Shares of BillionToOne barely budged at $94.30 despite the company announcing that its liquid biopsy cancer detection test cleared every primary and secondary endpoint in a pivotal trial — the kind of clinical milestone that typically sends diagnostics stocks surging. The muted reaction suggests Wall Street may have already priced in success, raising a critical question: how much upside is left before regulatory approval and commercial launch? BillionToOne's Cancer Blood Test Aces Its Biggest Trial — But Has Wall Street Already Moved On?
Shares of BillionToOne sat virtually flat at $94.30 despite the company clearing one of the most important milestones in diagnostics: a pivotal trial that hit every endpoint for its liquid biopsy cancer detection test. The peer-reviewed study compared its blood-based assay against a standard tumor-informed test for advanced cancer patients and found it matched or exceeded the established test's ability to monitor disease progression — without requiring a tissue sample. For a company racing to break into a market projected to be worth billions, the science just delivered. The stock didn't.
• The Trial Results Eliminate a Major Scientific Question Mark
The head-to-head study showed 94% concordance with the tumor-informed standard, and in every case where the two tests disagreed, clinical evidence supported BillionToOne's result. That's a powerful data package for regulators. The company plans to file for approval in the coming months, which would convert a research-stage asset into a commercial product. For shareholders, this de-risks the single biggest uncertainty around the company's oncology pipeline.
• Oncology Revenue Is Tiny but Growing Fast — and This Could Accelerate It
In Q1 2026, oncology revenue was just $10.7 million versus $96.5 million from prenatal testing — but oncology grew 392% year-over-year.
By Q2, oncology reached $13.7 million. Today, BillionToOne is overwhelmingly a prenatal screening company. A regulatory green light for its cancer test would open a second, much larger revenue stream and reduce the company's dependence on a single product line.
• The Market Opportunity Is Enormous, but So Is the Competition
The global liquid biopsy market was valued at $8.07 billion in 2026 and is projected to reach $24.87 billion by 2035, growing at roughly 13.4% annually.
But BillionToOne faces deep-pocketed rivals including Guardant Health, Foundation Medicine, Tempus AI, GRAIL, and Exact Sciences. Guardant alone generated $1.18 billion in trailing revenue. Winning meaningful share requires not just good science but reimbursement contracts and physician adoption.
• The Stock's Muted Reaction Suggests the Good News Was Already Baked In The stock ran from $93.07 to $95.75 in the days before the announcement, then drifted lower — a classic "buy the rumor, sell the news" pattern. Analysts' average price target sits at $125.88, implying roughly 33% upside , but with a market cap around $4.5 billion on guided revenue of $450–$465 million** , the stock already trades at roughly 10x forward sales — a premium that demands flawless execution from here.